AllSci News
Biogen's felzartamab wins first global approval in China for multiple myeloma
China's National Medical Products Administration (NMPA) has approved Jingshu (felzartamab), an anti-CD38 monoclonal antibody, in combination with...
Atrium collects second USD 15m milestone from BMS as cardiovascular RNA programs advance
San Diego-based Atrium Therapeutics (Nasdaq: RNA) has earned a second USD 15 million development milestone from Bristol Myers Squibb (NYSE: BMY) under their...
CSPC secures USD 30m from AstraZeneca for siRNA renal disease platform collaboration
CSPC Pharmaceutical Group (HKEX: 01093) has received the USD 30 million upfront payment from AstraZeneca under their collaboration, option and license...
MapLight bags USD 150m after muscarinic schizophrenia Phase II win
San Francisco and Boston-based MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced a USD 150 million private placement financing to fund two pivotal-stage...
Zentalis adds USD 80.5m as azenosertib nears pivotal test
San Diego-based Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the pricing of an underwritten public offering of 23 million shares of common stock at USD...
Khartis bags USD 95m for oral challenger to Tepezza
Khartis Therapeutics has emerged from stealth with USD 95 million in total funding, including a USD 50 million Series B led by Forge Life Science Partners,...
PhenoNet revives inhaled cromolyn for Phase III Alzheimer’s test
The FDA's clearance of a Phase III trial for an inhaled reformulation of a decades-old anti-allergy compound in Alzheimer's disease puts a privately held...
Pfizer, Valneva Lyme vaccine enters EU review after Phase III
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the 6-valent outer surface protein A...
BMS scores first CELMoD approval as FDA embraces MRD surrogate
Bristol Myers Squibb has received US FDA accelerated approval for Zenbexus (iberdomide), the first cereblon E3 ligase modulating drug (CELMoD) to reach the...
JW sets up epaminurad partnering push with Phase III gout win
A Phase III trial of epaminurad, a selective oral uricosuric agent for gout, has met its primary endpoint and demonstrated statistical superiority over an...
CRISPR Therapeutics takes one-shot gene editing into hypertension
CRISPR Therapeutics AG (Nasdaq: CRSP) has initiated a first-in-human clinical trial of CTX340, an in vivo gene editing therapy designed to permanently...
Cancer's 'dark proteome' becomes new hunting ground for drug targets
Dana-Farber Cancer Institute has received a USD 1.16 million National Cancer Institute OT2 award to map and therapeutically exploit the dark proteome — a...
IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies
China-based IASO Biotechnology ("IASO Bio") has completed the acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering company, adding...
Photys and Polymed put oral IRAK4 PROTAC degrader into first-in-human
Waltham, Massachusetts-based Photys Therapeutics and China-based Polymed Biopharmaceuticals have dosed the first healthy volunteers in a Phase I trial of...
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC
Shanghai Allist Pharmaceuticals (SSE: 688578) has licensed exclusive Greater China rights to AST12608/ARR-002, a dual-targeting MUC16/NaPi2b tetravalent...
The AllSci Brief
Free, systematic R&D and deal news. Daily.